Avadel Pharmaceuticals Investor Relations Material
Latest events
Q1 2025
Avadel Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Avadel Pharmaceuticals plc
Access all reports
Avadel Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing innovative treatments for chronic conditions, particularly in the central nervous system (CNS) field. The company's flagship product, LUMRYZ™, is an extended-release formulation of sodium oxybate used to treat cataplexy and excessive daytime sleepiness in adults with narcolepsy. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.
Key slides for Avadel Pharmaceuticals plc
Q1 2025
Avadel Pharmaceuticals plc
Q1 2025
Avadel Pharmaceuticals plc
Latest articles
)
Nintendo: From Game Boy and Pokémon to Switch 2 and Mario Kart
Nintendo went from card maker to cultural icon, shaping modern entertainment through hardware innovation and world-famous characters.
19 Jun 2025
)
Ron Vachris: From Forklift Driver to CEO at Costco
Ron Vachris took over as Costco CEO in 2024, following a 40-year journey from warehouse floors to the top of one of retail's most admired companies.
18 Jun 2025
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
Ticker symbol
AVDL
Country
🇺🇸 United States